Liver Ablative Radiotherapy utilizing Kilovoltage intrafraction monitoring

This trial aims to show that incorporating Kilovoltage Intrafraction Monitoring (KIM) into liver SABR improves treatment accuracy, patient treatment outcomes and treatment efficiency.

Primary Sponsor

University of Sydney

Collaborating Groups

TROG Cancer Research

Participating Centres

Accrual Target

46

Current Accrual

Expected Date of Accrual

March 2023

Closing Date of Accrual

LD

Trial Chairperson

Dr Yoo Young (Dominique) Lee, Princess Alexandra Hospital, QLD
Dr Tim Wang, Crown Princess Mary Cancer Centre, Westmead, NSW

Trial Contact

LARK@trog.com.au

Clinical Trial Registration

Related Post

August 2, 2022

Celebrating and bringing radiation medicine research to the forefront at our 2022 ASM

After a hiatus from in-person events due to COVID-19

February 28, 2022

Cancer trial participant hoping to help

The RAVES trial treating prostate cancer Participating in a